Advertisement

Picture [iito] Life Science Business Portals Media Data 2022 2 650x100px
Document › Details

EIT Health e.V.. (11/9/21). "Press Release: EIT Health-supported PhagoMed Acquired by BioNTech".

Organisations Organisation EIT Health e.V.
  Group EU (govt)
  Organisation 2 PhagoMed Biopharma GmbH
  Today BioNTech R&D (Austria) GmbH
  Group BioNTech (Group)
Products Product endolysin (recombinant phage enzyme)
  Product 2 antibiotic
Index term Index term PhagoMed–BioNTech: investment, 202111 acquisition estimated €150m of PhagoMed by BioNTech
Persons Person Beck, Jan-Philipp (EU (govt) 202111 CEO of EIT Health)
  Person 2 Belcredi, Alexander (PhagoMed 201906 Co-CEO + Co-Founder)
     


Today we are pleased to announce the acquisition of one of our supported start-ups; PhagoMed GmbH, by BioNTech SE. PhagoMed is developing novel synthetic lysin technology for precision antimicrobial treatments and was accelerated by EIT Health under our Gold Track programme.

According to the World Health Organisation, AMR is a global health and development threat requiring urgent action. AMR is caused by certain bacteria becoming resistant to even the most powerful antibiotics available today, due to overuse and misuse. A growing list of infections are becoming harder, and sometimes, impossible to treat, as antibiotics become less effective.1 Amongst other actions, new therapies to treat infections are needed to reduce the threat.

“Antimicrobial resistance is a huge concern for public health all over the world. Science and innovation is needed to find new and alternative solutions to antibiotics that are losing effectiveness, as we have seen from the last two years that we are not safe from infectious diseases. We saw great potential in PhagoMed to contribute towards solving this problem. We are honoured to have supported the innovative science and talented team at PhagoMed within our Gold Track Programme, and we congratulate them on their achievement,” said Jan-Philipp Beck, CEO of EIT Health.

PhagoMed use lysins to fight bacterial infections as an alternative to antibiotics. Lysins are enzymes produced by bacteriophages – the most abundant and diverse entity on earth that break down bacterial cell walls and thereby kill bacteria. Lysins are also very precise, meaning they selectively kill only specific groups of bacteria. PhagoMed’s LysinBuilder platform enables the development of synthetic lysins resulting in a novel class of targeted antibacterials and the potential to revolutionise the treatment of bacterial infections.

“We are thrilled to partner with BioNTech to further advance our synthetic lysin technology to address pressing health challenges,” said Alexander Belcredi and Lorenzo Corsini, co-CEOs of PhagoMed. “We thank the team and our mentors at EIT Health Gold Track for their support to help us refine our pipeline, platform and business model that enabled us to achieve our critical business goals in this short timeline.”

Vienna-based PhagoMed joined the Gold Track programme in June 2020 with a strong team and a promising idea, and were supported over a period of 12 months with defining their strategy and business model to accelerate them towards commercial success. To find out more about the Gold Track programme, please visit eithealth.eu/project/gold-track.


1. Who.int. 2021. Antimicrobial resistance. [online] Available at: [Accessed 9 November 2021].

   
Record changed: 2022-05-03

Advertisement

Picture [iito] Made Without Love 650x100px

More documents for EU (govt)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Kentro Design Corporate and Web Design for Start Ups 650x80px




» top